Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -38.63%.

  • Fortress Biotech's EBITDA Margin rose 11240.00% to -38.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -143.55%, marking a year-over-year increase of 2615.00%. This contributed to the annual value of -191.38% for FY2024, which is 2295.00% down from last year.
  • Latest data reveals that Fortress Biotech reported EBITDA Margin of -38.63% as of Q3 2025, which was up 82.62% from -222.22% recorded in Q2 2025.
  • Fortress Biotech's 5-year EBITDA Margin high stood at -38.63% for Q3 2025, and its period low was -473.63% during Q1 2023.
  • Over the past 3 years, Fortress Biotech's median EBITDA Margin value was -169.85% (recorded in 2025), while the average stood at -191.48%.
  • Within the past 5 years, the most significant YoY rise in Fortress Biotech's EBITDA Margin was 26,737bps (2023), while the steepest drop was 27,605bps (2023).
  • Fortress Biotech's EBITDA Margin (Quarterly) stood at -339.25% in 2021, then spiked by 620bps to -333.05% in 2022, then soared by 23,472bps to -98.34% in 2023, then crashed by 5,930bps to -157.64% in 2024, then surged by 11,240bps to -38.63% in 2025.
  • Its EBITDA Margin stands at -38.63% for Q3 2025, versus -222.22% for Q2 2025 and -169.85% for Q1 2025.